Company name Augmentiqs * Website www.augmentiqs.com *

CEO name Gabriel Siegel*

CATEGORY: Health IT/Digital

SESSIONS

• Digital Biomarkers & Digital Pathology: new tools to enhance therapy

o Executive Summary / Investment Rational

For over a decade, the world has been on the cusp of a digital pathology revolution. And while some AI companies have progressed nicely, and many clinical labs have purchased scanners for their diagnostic routine, the number of 'fully digital' labs is actually quite small and well below expected growth rates. What have we miscalculated?

o Core Technology

Augmentiqs is a technology for accessing AI and digital pathology applications from the existing microscope and classic pathology workflow. The rationale behind the company is that unlike radiology where the raw data is a digital image, in pathology the raw data is a glass slide, making the scanning process an extra step in a cost-sensitive workflow.

o Product Profile/Pipeline

Augmentiqs is a compelling technology for low and middle income countries which don't have the financial resources, nor civil or IT infrastructure for deploying scanning systems. Our collaboration efforts have focused on partnering with companies to automate processes within the pathology microscope routine which can save time and improve clinical efficacy. This includes single-click access to AI and LIS integration.

o Business Strategy

We've found that pathologists are seeking complete solutions, and as such the company's growth strategy has focused on forging relationships with synergistic providers, products and technologies such as AI, biomarkers and laboratory information systems.

o What's Next?

The Augmentiqs system has been used in novel studies, showing how the use of microscope-based digital pathology has cost and time saving advantages over whole slide imaging. However, the market is still inclined to scanning solutions, and as such a technology like Augmentiqs has to become a component of a larger solution provider.